// App-Quantinova.ai

9506 : Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).

Researchers

Presenter

  • Daniel Olson

Principal Investigators

  • Riyue Bao

  • Jacob B Allred

  • Carrie Strand

  • Yuanyuan Zha

  • Timothy C. Carll

  • Brian Labadie

  • Bruno R. Bastos

  • Marcus O. Butler

  • Pamela N. Munster

  • Gary K. Schwartz

  • Jason J. Luke

Medical Centers

  • University of Chicago Comprehensive Cancer Center, Chicago, IL

  • The University of Chicago Medical Center, Chicago, IL

  • Mayo Clinic, Rochester, MN

  • The University of Chicago Medical Center, Chicago, IL

  • The University of Chicago Medical Center, Chicago, IL

  • Cleveland Clinic Florida, Weston, FL

  • Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.

  • University of California, San Francisco, San Francisco, CA

  • Columbia University Medical Center, New York, NY

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

Outcome

  • Unknown

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01835145

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved